A PhaseII Study of JTE-052 Ointment in Pediatric Patients with Atopic Dermatitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223498

Enrollment

Registered

2017-03-31

Start date

2017-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

investigational material(s) Generic name etc : JTE-052A INN of investigational material : delgocitinib Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with atopic dermatitis Modified Eczema Area and Severity Index(mEASI) >=5

Exclusion criteria

Exclusion criteria: Patients with active infection Patients with history of tuberculosis Patients with hepatitis B/C virus carriers or history of hepatitis B/C virus infection Patients with history or presence of malignant tumor Use of topical corticosteroids (strongest or very strong) within 28 days before baseline Use of topical corticosteroids (strong, medium or weak) or tacrolimus hydrate ointment within 7 days before baseline

Design outcomes

Primary

Measure	Time frame
efficacy Percent change in mEASI	—

Secondary

Measure	Time frame
efficacy Eczema Area and Severity Index (EASI) Investigator's Global Assessment (IGA) Face and neck IGA Assessment of the target lesion (severity score and IGA) Pruritus score (assessed by the subjects or their legal representatives) Itching severity score (assessed by the investigator) Percent body surface area (%BSA) affected by eczema with inflammation Time (in days) to worsening of the target disease	—

Measure

Time frame

efficacy Eczema Area and Severity Index (EASI) Investigator's Global Assessment (IGA) Face and neck IGA Assessment of the target lesion (severity score and IGA) Pruritus score (assessed by the subjects or their legal representatives) Itching severity score (assessed by the investigator) Percent body surface area (%BSA) affected by eczema with inflammation Time (in days) to worsening of the target disease

—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026